| Literature DB >> 31770540 |
Abstract
The United States continues to face a public health emergency of opioid-related harm, the effects of which could be dramatically reduced through increased access to the opioid antagonist naloxone. Unfortunately, naloxone is too often unavailable when and where it is most needed, partly due to its continued status as a prescription medication. Although states and the federal Food and Drug Administration (FDA) have acted to increase access to naloxone, these changes are insufficient to address this unprecedented crisis. In this Commentary, we argue that FDA can and should immediately reclassify naloxone from prescription-only to over-the-counter status, a change that could save hundreds if not thousands of lives in the United States every year.Entities:
Keywords: Law; Naloxone; Opioids; Overdose
Mesh:
Substances:
Year: 2019 PMID: 31770540 DOI: 10.1016/j.ypmed.2019.105932
Source DB: PubMed Journal: Prev Med ISSN: 0091-7435 Impact factor: 4.018